Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,883 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06822582Recruiting
Pelvic health rehab after breast or gynecologic cancer
This trial tests a pelvic health rehabilitation program for people who have had breast or gynecologic cancer. It aims to help with pelvic floor problems like bladder or bowel issues that can start during or after treatment.
Edmonton, AlbertaAges 18 years+ - NCT05257135Recruiting
Study database and blood samples for colon cancer cachexia
This study collects clinical information and planned blood samples to better understand “cachexia,” which is a serious wasting condition that can happen with advanced cancer. It may help doctors find better ways to predict and manage symptoms in people with colon cancer who can’t have surgery.
MontpellierAges 18 years+ - NCT07402915RecruitingPhase 1
Study of AZD5335 with itraconazole in ovarian cancer
This study tests how the body handles the study drug AZD5335 when taken with itraconazole (a common antifungal). It is for people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer who have already tried standard treatments.
BatumiAges 18 years+ - NCT07401875RecruitingPhase 1
A study of HC-7366 with immunotherapy for advanced kidney cancer
This study tests an experimental drug (HC-7366) combined with standard immunotherapy for advanced kidney cancer. It aims to see if this combo can help control the cancer better, and checks safety and effectiveness.
Dallas, TexasAges 18 years+ - NCT07398690Recruiting
MRI-guided approach for prostate cancer diagnosis
This trial tests if using MRI and a blood test called PHI can help decide who needs a prostate biopsy. It aims to avoid unnecessary biopsies while still catching cancer early.
SeoulAges 20 years+ - NCT07401537RecruitingPhase 2
Comparing two schedules of immunotherapy for advanced triple-negative breast cancer
This trial tests whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer who have already completed 6 cycles of first-line treatment. It aims to see if a longer break between doses can be just as effective with fewer hospital visits.
Guangzhou, GuangdongAges 18–70 - NCT07405645Recruiting
Focused Ultrasound for Cancer Pain in the Head or Neck
This trial tests a non-invasive focused ultrasound treatment aimed at a specific brain area to reduce severe cancer-related pain in the head, neck, or upper chest. It may help if your pain hasn't responded to standard medications.
Boston, MassachusettsAges 18–85 - NCT07403630Recruiting
Tumor chemogenomic profiler for cancer patients of all ages
This trial uses a new testing platform to analyze the genes and proteins in your tumor, aiming to find the most effective treatments for people with cancer that has come back, is not responding to treatment, or has spread. It is designed for both children and adults with any type of blood cancer or solid tumor.
Palermo, PalermoAges 1 year+ - NCT07401199Recruiting
AI predicts immunotherapy response in advanced stomach cancer
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
Fuyang, AnhuiAges 18 years+ - NCT07393555RecruitingPhase 2
Treatment for advanced lung cancer after targeted therapy and chemotherapy
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
Berkeley, CaliforniaAges 18 years+ - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Atascadero, CaliforniaAges 18 years+ - NCT07396064Recruiting
Using a cancer care app to help underserved patients
This trial tests a remote monitoring platform (app and home devices) to improve care for cancer patients with limited access to healthcare. It aims to help people who face barriers like not speaking English or having only government insurance.
Columbus, OhioAges 18 years+ - NCT07393867RecruitingPhase 2
PSMA-guided radiation boost for prostate cancer
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Boston, MassachusettsAges 18 years+ - NCT07389512Recruiting
Pharmaceutical management in targeted radionuclide therapy study
This study is for adults who are getting targeted radionuclide therapy and have a pharmacist involved in managing their medicines. It looks at how the medication is handled to improve treatment safety and effectiveness.
BronAges 18 years+ - NCT04671511Recruiting
Check targeted lymph node surgery for early breast cancer
This study tests a more focused surgery approach to remove lymph nodes in the armpit for people with early breast cancer that has been found in 1–2 axillary lymph nodes. It may help guide more precise treatment while checking how well this approach works.
Montreal, QuebecAges 18 years+ - NCT07380867Enrolling by invitation
New marker test for marking colon tumors before surgery
This trial tests a new marker that glows under special light to help doctors see exactly where a colon tumor is during surgery. It may help make the surgery more precise.
Seoul, SeoulAges 19–80 - NCT07382583Recruiting
Study of a decision tool for endometrial cancer prevention
This study is developing a tool to help women decide if using a hormone-releasing intrauterine device (IUD) is right for them to lower their risk of endometrial cancer. Researchers are interviewing women at different risk levels and healthcare providers to make the tool useful and easy to understand.
Houston, TexasAges 18 years+ - NCT07373782RecruitingPhase 2/Phase 3
CPAP mask during radiation for breast cancer
This trial tests whether using a CPAP mask during daily radiation treatments for breast cancer can help protect your heart. It is for women who had a lumpectomy and need radiation to the left breast or to the right breast with lymph nodes.
LeuvenAges 40–80 - NCT07376174Recruiting
HER2-positive breast cancer and dual-target therapy study
This study looks at how well a combination of two targeted drugs (trastuzumab and pertuzumab) works for people with HER2-positive breast cancer that hasn't spread. It aims to understand how HER2 levels affect treatment outcomes after surgery.
Jinan, ShandongAges 18 years+ - NCT07372079RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for early triple-negative breast cancer
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
TianjinAges 18–75 - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07372716Recruiting
Blood thinner safety during cancer surgery
This trial studies the safety of managing blood thinners (like apixaban or warfarin) around the time of cancer surgery or procedures. It aims to help doctors understand how to best handle these medications to reduce risks.
OttawaAges 18 years+ - NCT07376707RecruitingPhase 1
Study of TGI-5 alone or with nivolumab for advanced solid tumors
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
ShanghaiAges 18 years+ - NCT07372261Enrolling by invitation
Predicting breast cancer spread risk
This study tests a method to predict if early-stage breast cancer might spread to other parts of the body. It uses leftover tumor tissue to help doctors plan your treatment.
San Giovanni Rotondo, FGAges 18 years+
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,883 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.